ABSTRACT

Introduction

Esophageal cancer (EC) is the seventh most common malignancy in the world. The standard treatment for advanced EC patients is systemic chemotherapy, but few effective cytotoxic agents are available. Recently, nivolumab, a human monoclonal immunoglobulin G4 antibody that inhibits programmed cell death protein 1, has been tested for the treatment of advanced squamous cell carcinoma (ESCC) patients. The ATTRACTION-1 trial showed a promising efficacy of nivolumab monotherapy for advanced ESCC patients after prior chemotherapy. The ATTRACTION-3 phase III trial showed the superiority of nivolumab monotherapy over taxane monotherapy for advanced ESCC patients as a second-line treatment. The CheckMate-577 trial also showed survival benefits of postoperative nivolumab monotherapy in patients with resectable EC.

Areas covered

This review mainly outlines emerging data on nivolumab for patients with advanced ESCC after prior chemotherapy. Additionally, this review includes data from the CheckMate-577 trial for patients with resectable EC.

Expert opinion

Nivolumab has been approved by the US Food and Drug Administration for treatment after prior chemotherapy in patients with advanced ESCC. Several trials evaluating nivolumab-containing treatments are ongoing in patients with not only advanced EC, but also locally advanced EC, and these investigational treatments might improve the clinical outcomes of EC patients.

中文翻译：

---

纳武利尤单抗治疗食管鳞状细胞癌的新数据

摘要

介绍

食管癌（EC）是世界上第七大最常见的恶性肿瘤。晚期 EC 患者的标准治疗是全身化疗，但有效的细胞毒药物很少。最近，nivolumab 是一种抑制程序性细胞死亡蛋白 1 的人单克隆免疫球蛋白 G4 抗体，已被测试用于治疗晚期鳞状细胞癌 (ESCC) 患者。ATTRACTION-1 试验显示，纳武利尤单抗单药疗法对既往化疗后的晚期 ESCC 患者具有良好的疗效。ATTRACTION-3 III 期试验显示，作为二线治疗的晚期 ESCC 患者，纳武利尤单抗单药治疗优于紫杉烷单药治疗。CheckMate-577 试验还显示术后纳武利尤单抗单药治疗对可切除 EC 患者的生存益处。

涵盖的领域

本综述主要概述了先前化疗后晚期 ESCC 患者使用 nivolumab 的新数据。此外，本综述还包括来自 CheckMate-577 试验的可切除 EC 患者的数据。

专家意见

Nivolumab 已被美国食品和药物管理局批准用于晚期 ESCC 患者先前化疗后的治疗。几项评估含 nivolumab 治疗的试验不仅在晚期 EC 患者中进行，而且还在局部晚期 EC 患者中进行，这些研究性治疗可能会改善 EC 患者的临床结果。